Plain Language Summary of the MajesTEC-1 Study of Teclistamab for the Treatment of People with Relapsed or Refractory Multiple Myeloma.
Future oncology（2023）
关键词
BCMA,bispecific antibody,CD3,clinical trial,immunotherapy,lay summary,multiple myeloma,plain language summary,relapsed,refractory multiple myeloma,teclistamab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要